|
Sign In to gain access to subscriptions and/or personal tools.
|
Open-Label Trial of Atomoxetine Hydrochloride in Adults With ADHD
Mats Johnson, MD*,
Mats Cederlund, MD, PhD,
Maria Råstam, MD, PhD,
Björn Areskoug, MSc,
and
Christopher Gillberg, MD, PhD
* To whom correspondence should be addressed. E-mail: mats.k.johnson{at}vgregion.se.
 |
Abstract |
|---|
Background: While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults. Methods: Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders. Results: Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood pressure), decreasing efficacy or non-compliance. Conclusion: Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects.
First published on May 20, 2009
Journal of Attention Disorders 2009, doi:10.1177/1087054709332372
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
